APO Research
Talk to an analyst

APO RESEARCH · REPORT

Orphan Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Orphan Drugs Market Analysis and Forecast 2026-2032

29 December 2025199 pages

Choose your research edition.

Industry ResearchOrphan Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Orphan Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Orphan Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Orphan Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Orphan Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Orphan Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Orphan Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Orphan Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Orphan Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Orphan Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Orphan Drugs include AstraZeneca, AbbVie, Amgen, Bristol-Myers Squibb, Biogen, Vertex Pharmaceuticals, Pfizer, Eli Lilly and Roche, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Orphan Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Orphan Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Orphan Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Orphan Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Orphan Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Orphan Drugs revenue, projected growth trends, production technology, application and end-user industry.

Orphan Drugs Segment by Company

AstraZeneca

AbbVie

Amgen

Bristol-Myers Squibb

Biogen

Vertex Pharmaceuticals

Pfizer

Eli Lilly

Roche

Novartis

Johnson & Johnson

Sanofi

Takeda

Orphan Drugs Segment by Type

Metabolic Disorders

Pulmonary

Endocrinology

Neurology

Cardio-vascular

Hematology

Oncology

Others

Orphan Drugs Segment by Application

Adult

Teenager

Baby and Child

Other

Orphan Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Orphan Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Orphan Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Orphan Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Orphan Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Orphan Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Orphan Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Orphan Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Metabolic Disorders Major Player Table 3. Pulmonary Major Player Table 4. Endocrinology Major Player Table 5. Neurology Major Player Table 6. Cardio-vascular Major Player Table 7. Hematology Major Player Table 8. Oncology Major Player Table 9. Others Major Player Table 10. Global Orphan Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 11. Adult Major Player Table 12. Teenager Major Player Table 13. Baby and Child Major Player Table 14. Other Major Player Table 15. Orphan Drugs Industry Trends Table 16. Orphan Drugs Industry Drivers Table 17. Orphan Drugs Industry Opportunities and Challenges Table 18. Orphan Drugs Industry Restraints Table 19. Global Orphan Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 20. Global Orphan Drugs Market Size by Region (2021-2026) & (US$ Million) Table 21. Global Orphan Drugs Market Share by Region (2021-2026) Table 22. Global Orphan Drugs Market Size by Region (2027-2032) & (US$ Million) Table 23. Global Orphan Drugs Market Share by Region (2027-2032) Table 24. Global Orphan Drugs Revenue by Players (US$ Million) & (2021-2026) Table 25. Global Orphan Drugs Revenue Market Share by Players (2021-2026) Table 26. Global Orphan Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 27. Global Orphan Drugs Key Players Headquarters & Area Served Table 28. Global Orphan Drugs Players, Product Type & Application Table 29. Global Orphan Drugs Players Establishment Date Table 30. Global Players Market Concentration Ratio (CR5 and HHI) Table 31. Global Orphan Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Orphan Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Orphan Drugs Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Orphan Drugs Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Orphan Drugs Revenue Market Share by Type (2021-2026) Table 36. Global Orphan Drugs Revenue Market Share by Type (2027-2032) Table 37. Global Orphan Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Orphan Drugs Revenue by Application (2021-2026) & (US$ Million) Table 39. Global Orphan Drugs Revenue by Application (2027-2032) & (US$ Million) Table 40. Global Orphan Drugs Revenue Market Share by Application (2021-2026) Table 41. Global Orphan Drugs Revenue Market Share by Application (2027-2032) Table 42. AstraZeneca Company Information Table 43. AstraZeneca Business Overview Table 44. AstraZeneca Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. AstraZeneca Orphan Drugs Product Portfolio Table 46. AstraZeneca Recent Development Table 47. AbbVie Company Information Table 48. AbbVie Business Overview Table 49. AbbVie Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. AbbVie Orphan Drugs Product Portfolio Table 51. AbbVie Recent Development Table 52. Amgen Company Information Table 53. Amgen Business Overview Table 54. Amgen Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Amgen Orphan Drugs Product Portfolio Table 56. Amgen Recent Development Table 57. Bristol-Myers Squibb Company Information Table 58. Bristol-Myers Squibb Business Overview Table 59. Bristol-Myers Squibb Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Bristol-Myers Squibb Orphan Drugs Product Portfolio Table 61. Bristol-Myers Squibb Recent Development Table 62. Biogen Company Information Table 63. Biogen Business Overview Table 64. Biogen Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Biogen Orphan Drugs Product Portfolio Table 66. Biogen Recent Development Table 67. Vertex Pharmaceuticals Company Information Table 68. Vertex Pharmaceuticals Business Overview Table 69. Vertex Pharmaceuticals Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Vertex Pharmaceuticals Orphan Drugs Product Portfolio Table 71. Vertex Pharmaceuticals Recent Development Table 72. Pfizer Company Information Table 73. Pfizer Business Overview Table 74. Pfizer Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Pfizer Orphan Drugs Product Portfolio Table 76. Pfizer Recent Development Table 77. Eli Lilly Company Information Table 78. Eli Lilly Business Overview Table 79. Eli Lilly Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Eli Lilly Orphan Drugs Product Portfolio Table 81. Eli Lilly Recent Development Table 82. Roche Company Information Table 83. Roche Business Overview Table 84. Roche Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Roche Orphan Drugs Product Portfolio Table 86. Roche Recent Development Table 87. Novartis Company Information Table 88. Novartis Business Overview Table 89. Novartis Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 90. Novartis Orphan Drugs Product Portfolio Table 91. Novartis Recent Development Table 92. Johnson & Johnson Company Information Table 93. Johnson & Johnson Business Overview Table 94. Johnson & Johnson Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Johnson & Johnson Orphan Drugs Product Portfolio Table 96. Johnson & Johnson Recent Development Table 97. Sanofi Company Information Table 98. Sanofi Business Overview Table 99. Sanofi Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Sanofi Orphan Drugs Product Portfolio Table 101. Sanofi Recent Development Table 102. Takeda Company Information Table 103. Takeda Business Overview Table 104. Takeda Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Takeda Orphan Drugs Product Portfolio Table 106. Takeda Recent Development Table 107. North America Orphan Drugs Revenue by Type (2021-2026) & (US$ Million) Table 108. North America Orphan Drugs Revenue by Type (2027-2032) & (US$ Million) Table 109. North America Orphan Drugs Revenue by Application (2021-2026) & (US$ Million) Table 110. North America Orphan Drugs Revenue by Application (2027-2032) & (US$ Million) Table 111. North America Orphan Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. North America Orphan Drugs Revenue by Country (2021-2026) & (US$ Million) Table 113. North America Orphan Drugs Revenue by Country (US$ Million) & (2027-2032) Table 114. Europe Orphan Drugs Revenue by Type (2021-2026) & (US$ Million) Table 115. Europe Orphan Drugs Revenue by Type (2027-2032) & (US$ Million) Table 116. Europe Orphan Drugs Revenue by Application (2021-2026) & (US$ Million) Table 117. Europe Orphan Drugs Revenue by Application (2027-2032) & (US$ Million) Table 118. Europe Orphan Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Europe Orphan Drugs Revenue by Country (2021-2026) & (US$ Million) Table 120. Europe Orphan Drugs Revenue by Country (US$ Million) & (2027-2032) Table 121. China Orphan Drugs Revenue by Type (2021-2026) & (US$ Million) Table 122. China Orphan Drugs Revenue by Type (2027-2032) & (US$ Million) Table 123. China Orphan Drugs Revenue by Application (2021-2026) & (US$ Million) Table 124. China Orphan Drugs Revenue by Application (2027-2032) & (US$ Million) Table 125. Asia Orphan Drugs Revenue by Type (2021-2026) & (US$ Million) Table 126. Asia Orphan Drugs Revenue by Type (2027-2032) & (US$ Million) Table 127. Asia Orphan Drugs Revenue by Application (2021-2026) & (US$ Million) Table 128. Asia Orphan Drugs Revenue by Application (2027-2032) & (US$ Million) Table 129. Asia Orphan Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 130. Asia Orphan Drugs Revenue by Region (US$ Million) & (2021-2026) Table 131. Asia Orphan Drugs Revenue by Region (US$ Million) & (2027-2032) Table 132. SAMEA Orphan Drugs Revenue by Type (2021-2026) & (US$ Million) Table 133. SAMEA Orphan Drugs Revenue by Type (2027-2032) & (US$ Million) Table 134. SAMEA Orphan Drugs Revenue by Application (2021-2026) & (US$ Million) Table 135. SAMEA Orphan Drugs Revenue by Application (2027-2032) & (US$ Million) Table 136. SAMEA Orphan Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. SAMEA Orphan Drugs Revenue by Country (2021-2026) & (US$ Million) Table 138. SAMEA Orphan Drugs Revenue by Country (US$ Million) & (2027-2032) Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. Orphan Drugs Image Figure 2. Global Orphan Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Orphan Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Metabolic Disorders Image Figure 5. Pulmonary Image Figure 6. Endocrinology Image Figure 7. Neurology Image Figure 8. Cardio-vascular Image Figure 9. Hematology Image Figure 10. Oncology Image Figure 11. Others Image Figure 12. Global Orphan Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Orphan Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 14. Adult Image Figure 15. Teenager Image Figure 16. Baby and Child Image Figure 17. Other Image Figure 18. Global Orphan Drugs Market Size (US$ Million) & (2021-2032) Figure 19. Global Orphan Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 20. Global Orphan Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 21. Global Orphan Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Orphan Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Orphan Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Orphan Drugs Revenue Market Share by Type (2021-2032) Figure 26. Global Orphan Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Orphan Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 28. Global Orphan Drugs Revenue Market Share by Application (2021-2032) Figure 29. North America Orphan Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. North America Orphan Drugs Revenue Share by Type (2021-2032) Figure 31. North America Orphan Drugs Revenue Share by Application (2021-2032) Figure 32. North America Orphan Drugs Revenue Share by Country (2021-2032) Figure 33. United States Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Canada Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Mexico Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Europe Orphan Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 37. Europe Orphan Drugs Revenue Share by Type (2021-2032) Figure 38. Europe Orphan Drugs Revenue Share by Application (2021-2032) Figure 39. Europe Orphan Drugs Revenue Share by Country (2021-2032) Figure 40. Germany Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. France Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. U.K. Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Italy Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Spain Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Russia Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Netherlands Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. Nordic Countries Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. China Orphan Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. China Orphan Drugs Revenue Share by Type (2021-2032) Figure 50. China Orphan Drugs Revenue Share by Application (2021-2032) Figure 51. Asia Orphan Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 52. Asia Orphan Drugs Revenue Share by Type (2021-2032) Figure 53. Asia Orphan Drugs Revenue Share by Application (2021-2032) Figure 54. Asia Orphan Drugs Revenue Share by Region (2021-2032) Figure 55. Japan Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. South Korea Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. India Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Australia Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Taiwan Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Southeast Asia Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. SAMEA Orphan Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 62. SAMEA Orphan Drugs Revenue Share by Type (2021-2032) Figure 63. SAMEA Orphan Drugs Revenue Share by Application (2021-2032) Figure 64. SAMEA Orphan Drugs Revenue Share by Country (2021-2032) Figure 65. Brazil Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Argentina Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Chile Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Colombia Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Peru Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Saudi Arabia Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Israel Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. UAE Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Turkey Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Iran Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Egypt Orphan Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Metabolic Disorders
  • Pulmonary
  • Endocrinology
  • Neurology
  • Cardio-vascular
  • Hematology
  • Oncology
  • Others
Applications
  • Adult
  • Teenager
  • Baby and Child
  • Other
Companies covered
  • AstraZeneca
  • AbbVie
  • Amgen
  • Bristol-Myers Squibb
  • Biogen
  • Vertex Pharmaceuticals
  • Pfizer
  • Eli Lilly
  • Roche
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Orphan Drugs Market by Type
  3. 1.2.1 Global Orphan Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Metabolic Disorders
  5. 1.2.3 Pulmonary
  6. 1.2.4 Endocrinology
  7. 1.2.5 Neurology
  8. 1.2.6 Cardio-vascular
  9. 1.2.7 Hematology
  10. 1.2.8 Oncology
  11. 1.2.9 Others
  12. 1.3 Orphan Drugs Market by Application
  13. 1.3.1 Global Orphan Drugs Market Size by Application, 2021 VS 2025 VS 2032
  14. 1.3.2 Adult
  15. 1.3.3 Teenager
  16. 1.3.4 Baby and Child
  17. 1.3.5 Other
  18. 1.4 Assumptions and Limitations
  19. 1.5 Study Goals and Objectives
2 Orphan Drugs Market Dynamics
  1. 2.1 Orphan Drugs Industry Trends
  2. 2.2 Orphan Drugs Industry Drivers
  3. 2.3 Orphan Drugs Industry Opportunities and Challenges
  4. 2.4 Orphan Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Orphan Drugs Market Perspective (2021-2032)
  2. 3.2 Global Orphan Drugs Growth Trends by Region
  3. 3.2.1 Global Orphan Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Orphan Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Orphan Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Orphan Drugs Revenue by Players
  2. 4.1.1 Global Orphan Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Orphan Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Orphan Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Orphan Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Orphan Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Orphan Drugs Players, Product Type & Application
  8. 4.5 Global Orphan Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Orphan Drugs Market CR5 and HHI
  11. 4.6.3 2025 Orphan Drugs Tier 1, Tier 2, and Tier 3
5 Orphan Drugs Market Size by Type
  1. 5.1 Global Orphan Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Orphan Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Orphan Drugs Revenue Market Share by Type (2021-2032)
6 Orphan Drugs Market Size by Application
  1. 6.1 Global Orphan Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Orphan Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Orphan Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 AstraZeneca
  2. 7.1.1 AstraZeneca Company Information
  3. 7.1.2 AstraZeneca Business Overview
  4. 7.1.3 AstraZeneca Orphan Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 AstraZeneca Orphan Drugs Product Portfolio
  6. 7.1.5 AstraZeneca Recent Developments
  7. 7.2 AbbVie
  8. 7.2.1 AbbVie Company Information
  9. 7.2.2 AbbVie Business Overview
  10. 7.2.3 AbbVie Orphan Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 AbbVie Orphan Drugs Product Portfolio
  12. 7.2.5 AbbVie Recent Developments
  13. 7.3 Amgen
  14. 7.3.1 Amgen Company Information
  15. 7.3.2 Amgen Business Overview
  16. 7.3.3 Amgen Orphan Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Amgen Orphan Drugs Product Portfolio
  18. 7.3.5 Amgen Recent Developments
  19. 7.4 Bristol-Myers Squibb
  20. 7.4.1 Bristol-Myers Squibb Company Information
  21. 7.4.2 Bristol-Myers Squibb Business Overview
  22. 7.4.3 Bristol-Myers Squibb Orphan Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bristol-Myers Squibb Orphan Drugs Product Portfolio
  24. 7.4.5 Bristol-Myers Squibb Recent Developments
  25. 7.5 Biogen
  26. 7.5.1 Biogen Company Information
  27. 7.5.2 Biogen Business Overview
  28. 7.5.3 Biogen Orphan Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Biogen Orphan Drugs Product Portfolio
  30. 7.5.5 Biogen Recent Developments
  31. 7.6 Vertex Pharmaceuticals
  32. 7.6.1 Vertex Pharmaceuticals Company Information
  33. 7.6.2 Vertex Pharmaceuticals Business Overview
  34. 7.6.3 Vertex Pharmaceuticals Orphan Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Vertex Pharmaceuticals Orphan Drugs Product Portfolio
  36. 7.6.5 Vertex Pharmaceuticals Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Orphan Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Orphan Drugs Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 Eli Lilly
  44. 7.8.1 Eli Lilly Company Information
  45. 7.8.2 Eli Lilly Business Overview
  46. 7.8.3 Eli Lilly Orphan Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Eli Lilly Orphan Drugs Product Portfolio
  48. 7.8.5 Eli Lilly Recent Developments
  49. 7.9 Roche
  50. 7.9.1 Roche Company Information
  51. 7.9.2 Roche Business Overview
  52. 7.9.3 Roche Orphan Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Roche Orphan Drugs Product Portfolio
  54. 7.9.5 Roche Recent Developments
  55. 7.10 Novartis
  56. 7.10.1 Novartis Company Information
  57. 7.10.2 Novartis Business Overview
  58. 7.10.3 Novartis Orphan Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Novartis Orphan Drugs Product Portfolio
  60. 7.10.5 Novartis Recent Developments
  61. 7.11 Johnson & Johnson
  62. 7.11.1 Johnson & Johnson Company Information
  63. 7.11.2 Johnson & Johnson Business Overview
  64. 7.11.3 Johnson & Johnson Orphan Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Johnson & Johnson Orphan Drugs Product Portfolio
  66. 7.11.5 Johnson & Johnson Recent Developments
  67. 7.12 Sanofi
  68. 7.12.1 Sanofi Company Information
  69. 7.12.2 Sanofi Business Overview
  70. 7.12.3 Sanofi Orphan Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Sanofi Orphan Drugs Product Portfolio
  72. 7.12.5 Sanofi Recent Developments
  73. 7.13 Takeda
  74. 7.13.1 Takeda Company Information
  75. 7.13.2 Takeda Business Overview
  76. 7.13.3 Takeda Orphan Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Takeda Orphan Drugs Product Portfolio
  78. 7.13.5 Takeda Recent Developments
8 North America
  1. 8.1 North America Orphan Drugs Revenue (2021-2032)
  2. 8.2 North America Orphan Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Orphan Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Orphan Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Orphan Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Orphan Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Orphan Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Orphan Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Orphan Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Orphan Drugs Revenue by Country
  11. 8.6.1 North America Orphan Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Orphan Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Orphan Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Orphan Drugs Revenue (2021-2032)
  2. 9.2 Europe Orphan Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Orphan Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Orphan Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Orphan Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Orphan Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Orphan Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Orphan Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Orphan Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Orphan Drugs Revenue by Country
  11. 9.6.1 Europe Orphan Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Orphan Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Orphan Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Orphan Drugs Revenue (2021-2032)
  2. 10.2 China Orphan Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Orphan Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Orphan Drugs Revenue by Type (2027-2032)
  5. 10.3 China Orphan Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Orphan Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Orphan Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Orphan Drugs Revenue by Application (2027-2032)
  9. 10.5 China Orphan Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Orphan Drugs Revenue (2021-2032)
  2. 11.2 Asia Orphan Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Orphan Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Orphan Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Orphan Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Orphan Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Orphan Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Orphan Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Orphan Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Orphan Drugs Revenue by Country
  11. 11.6.1 Asia Orphan Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Orphan Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Orphan Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Orphan Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Orphan Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Orphan Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Orphan Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Orphan Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Orphan Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Orphan Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Orphan Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Orphan Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Orphan Drugs Revenue by Country
  11. 12.6.1 SAMEA Orphan Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Orphan Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Orphan Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst